Physician profile
Patrick Gillihan
NPI 1255715579
$981.56
in general payments reported to CMS, 2019-2025
15 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $55.73 · 2021: $51.37 · 2022: $28.17 · 2023: $183 · 2024: $295 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $268.52 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $192.26 | 2023-2025 | Jublia |
| Stryker Corporation | $111.69 | 2021-2024 | Augment Injectable, Anchorage, Ortholoc 3di |
| Djo, LLC | $59.46 | 2024 | Cmf |
| Averitas Pharma INC. | $54.33 | 2023-2024 | Qutenza |
| Organogenesis INC. | $52.21 | 2021-2022 | |
| Integra Lifesciences Corporation | $40.95 | 2020 | |
| Medtronic, INC. | $35.20 | 2023 | Venaseal |
| Horizon Therapeutics Plc | $31.09 | 2023 | Krystexxa |
| Curonix LLC | $30.76 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Paratek Pharmaceuticals, INC. | $30.39 | 2024 | Nuzyra |
| Mimedx Group, INC. | $26.93 | 2025 | |
| Amgen INC. | $18.67 | 2024 | Krystexxa |
| Nevro Corp. | $15.83 | 2021 | |
| Advanced Oxygen Therapy INC. | $13.27 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gillihan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.